Article
Author(s):
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
For the first time, researchers have identified genetic variants that are associated with an increased risk of progressive multifocal leukoencephalopathy, a rare and often lethal brain disorder that develops in a wide range of immunosuppressed groups and can occur as a serious adverse event from exposure to immunosuppressives.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN, who joined the show to discuss the clinical trial results for lecanemab (Biogen/Eisai) that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more. [LISTEN TIME: 21 minutes]
In the latest edition of our in-depth Q&A series, the chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.
In a conversation with NeurologyLive®, the professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]
In the final episode of this NeurologyLive® series, advanced practice providers Wendy L. Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP; and Debra Davis, CRNP, share their final pearls of wisdom with their colleagues as it pertains to the management of sleep disorders.